Wednesday, July 8, 2026

pharma · Nasopharyngeal Carcinoma · Hepatocellular Carcinoma

Chinese Academy of

Chinese Academy of is a pharma organization headquartered in TAIZHOU, CN. Primary therapeutic focus areas include Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, COVID-19, Breast Cancer, Coronary Artery Disease. Nova

China, TAIZHOU, CN HQ
170 Employees
NMPA registrant Type
Company details
Status
Public
HQ
China, TAIZHOU, CN
Employees
170
Programs
1328
Drugs
711
Patents
335
Clinical program

MIYAIRI 588

Approved · small molecule · Depression Mild

MIYAIRI 588 for Depression Mild is a Approved program (small_molecule) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).

Internal code CMUH111-REC3-178

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase
Approved
Modality
small_molecule
Indication
Depression Mild
Status
completed
Trials
1

Clinical trials